ZKSCAN4 Antibody

What is ZKSCAN4 and why is it significant in research?

ZKSCAN4 (Zinc finger with KRAB and SCAN domains 4) is a protein also known as Zinc Finger Protein 307 (ZNF307). It has significant research importance due to its expression in pluripotent stem cells, gametes, and early embryos, where it functions to extend telomeres, enhance genome stability, and improve karyotypes in embryonic stem cells. The protein binds to the TGCACAC motif located in CA/TG microsatellite repeats, which are known to form unstable left-handed duplexes (Z-DNA) that can induce double-strand DNA breaks and mutations. These functions make ZKSCAN4 an important target for studies related to genomic stability, stem cell biology, and early development .

What types of ZKSCAN4 antibodies are available for research applications?

Researchers have access to a diverse range of ZKSCAN4 antibodies, including both polyclonal and monoclonal variants with different host species. Notable examples include rabbit polyclonal antibodies targeting internal regions of human ZKSCAN4, mouse monoclonal antibodies (such as clone 1D2) targeting specific amino acid regions (AA 1-545, AA 38-87), and antibodies with varying species reactivities (human, mouse, horse, cow, monkey). These antibodies come in unconjugated forms and have been validated for multiple applications including Western Blotting, ELISA, Immunohistochemistry, and Immunofluorescence .

How do I select the appropriate ZKSCAN4 antibody for my experimental design?

When selecting a ZKSCAN4 antibody, consider several critical parameters: (1) species reactivity—ensure compatibility with your experimental model (human and mouse are most common); (2) application suitability—verify validation for your specific technique (WB, ELISA, IHC, or IF); (3) epitope location—choose antibodies targeting internal regions for general detection or specific domains for functional studies; (4) clonality—polyclonal antibodies offer broader epitope recognition while monoclonals provide higher specificity; and (5) validation evidence—prioritize antibodies with demonstrated specificity for endogenous ZKSCAN4 levels. For studying specific functional domains, select antibodies targeting relevant protein regions such as the KRAB or SCAN domains .

What are the validated applications for ZKSCAN4 antibodies in current research?

ZKSCAN4 antibodies have been validated for multiple research applications with varying degrees of optimization. Western blotting (WB) allows detection of endogenous ZKSCAN4 protein expression levels across different cell types and experimental conditions. Immunohistochemistry (IHC), particularly with paraffin-embedded sections (IHC-p), enables visualization of ZKSCAN4 expression patterns in tissue contexts. Immunofluorescence (IF) provides subcellular localization information, revealing ZKSCAN4's nuclear distribution patterns. ELISA applications offer quantitative measurement of ZKSCAN4 proteins. Additionally, some antibodies have been successfully employed in chromatin immunoprecipitation followed by sequencing (ChIP-seq) to identify genome-wide binding sites of endogenous ZKSCAN4 in both mouse and human ES cells .

How can I optimize Western blot protocols for ZKSCAN4 detection?

For optimal ZKSCAN4 detection via Western blotting, implement these research-validated steps: (1) Efficient protein extraction—use RIPA buffer supplemented with protease inhibitors for nuclear proteins; (2) Sample preparation—load 20-40 μg of total protein per lane after heat denaturation; (3) Gel selection—use 8-10% SDS-PAGE gels for better resolution of ZKSCAN4 (expected molecular weight range); (4) Transfer optimization—employ wet transfer methods (25V overnight or 100V for 1-2 hours) for complete transfer of larger proteins; (5) Blocking—use 5% non-fat milk in TBST to minimize background; (6) Primary antibody incubation—dilute according to manufacturer specifications (typically 1:1000) and incubate overnight at 4°C; (7) Detection system—HRP-conjugated secondary antibodies with enhanced chemiluminescence provide sufficient sensitivity for visualizing endogenous levels. Always include positive controls (ZKSCAN4-expressing cell lines) and negative controls (non-expressing tissues) for validation .

What methodological approaches are effective for co-immunoprecipitation studies with ZKSCAN4?

For successful co-immunoprecipitation studies with ZKSCAN4, implement this validated methodology: (1) Cell preparation—use cells with confirmed ZKSCAN4 expression (such as retinoic acid-treated mouse ES cells or DUX4-overexpressed human ES cells); (2) Lysis conditions—employ gentle, non-denaturing buffers (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0) with protease inhibitors; (3) Pre-clearing—reduce non-specific binding by pre-incubating lysates with protein A/G beads; (4) Antibody selection—use affinity-purified ZKSCAN4 antibodies (such as rabbit polyclonals against internal regions); (5) Incubation parameters—combine lysate with antibody overnight at 4°C with gentle rotation; (6) Washing stringency—perform multiple washes of increasing stringency to remove non-specific interactions; (7) Elution and analysis—elute with SDS sample buffer and analyze via Western blotting. This approach has successfully demonstrated interaction between endogenous ZKSCAN4 and glucocorticoid receptor in Hct116 cells .

How can ChIP-seq be optimized for studying ZKSCAN4 binding sites in the genome?

For optimizing ChIP-seq studies of ZKSCAN4 genomic binding sites, implement this comprehensive approach: (1) Cell preparation—increase ZKSCAN4-positive cells by retinoic acid treatment (20-30% positivity in mouse ES cells) or DUX4 overexpression (for human ES cells); (2) Crosslinking parameters—use 1% formaldehyde for 10 minutes at room temperature; (3) Chromatin shearing—sonicate to achieve fragments of 200-500 bp; (4) Antibody selection—employ validated anti-ZKSCAN4 antibodies with demonstrated ChIP efficiency; (5) Quality controls—include input controls and IgG antibody controls; (6) Data analysis—align sequence reads to the appropriate genome (mm10 for mouse, hg19 for human) using bowtie with maximum one error and one hit parameters; (7) Peak calling—use MACS2 with q-value threshold less than 0.2; (8) Motif analysis—apply MEME-ChIP to identify the TGCACAC binding motif. This methodology has successfully identified ZSCAN4 binding to CA/TG microsatellite repeats in both mouse and human genomes .

What strategies can overcome challenges in detecting low-abundance ZKSCAN4 expression?

Due to ZKSCAN4's transient and often low-level expression (1-5% of mouse ES cells express endogenous ZKSCAN4), implement these specialized detection strategies: (1) Cell enrichment—use FACS sorting with ZSCAN4 promoter-driven fluorescent reporters; (2) Expression induction—employ retinoic acid treatment (increases ZSCAN4-positive cells to 20-30% in mouse ES cells) or DUX4 overexpression (in human ES cells); (3) Signal amplification—utilize tyramide signal amplification for immunohistochemistry or immunofluorescence; (4) Enhanced Western blotting—implement high-sensitivity ECL substrates and longer exposure times; (5) RNA detection—consider RT-qPCR with validated primer sets for transcript quantification; (6) Single-cell analysis—employ single-cell RNA-seq or imaging to capture heterogeneous expression; (7) Pooled sampling—increase cell numbers to enhance detection of rare positive populations. These approaches have successfully detected endogenous ZKSCAN4 in several experimental contexts .

How can researchers distinguish between different ZKSCAN4 protein isoforms or family members?

To effectively distinguish between ZKSCAN4 isoforms or related family members, implement this multifaceted approach: (1) Antibody epitope mapping—select antibodies targeting unique regions not conserved among family members (e.g., antibodies against internal regions rather than conserved zinc finger domains); (2) Molecular weight discrimination—carefully analyze band patterns on Western blots, as different isoforms may present distinct molecular weights; (3) Control samples—include samples with overexpressed specific ZKSCAN4 isoforms as positive controls; (4) Knockdown validation—perform siRNA/shRNA knockdown of specific isoforms to confirm antibody specificity; (5) Mass spectrometry—employ MS-based approaches for definitive isoform identification; (6) Domain-specific functional assays—design experiments targeting unique functions of specific domains. This combined approach minimizes cross-reactivity with other zinc finger proteins (ZNF307, ZNF427) or related ZKSCAN family members when studying ZKSCAN4 .

What experimental systems best model ZKSCAN4 functions in genome stability?

For investigating ZKSCAN4's role in genome stability, these experimental systems provide optimal research platforms: (1) Mouse embryonic stem cells—endogenously express ZKSCAN4 in a small percentage (1-5%) of cells, with expression inducible via retinoic acid treatment; (2) Human embryonic stem cells—express ZKSCAN4 upon DUX4 overexpression; (3) ZSCAN4 knockout models—generate using CRISPR/Cas9 to assess loss-of-function phenotypes; (4) Inducible overexpression systems—create tetracycline-controlled ZSCAN4 expression to study gain-of-function effects; (5) Telomere length assays—measure using quantitative fluorescence in situ hybridization or telomere restriction fragment analysis to assess ZSCAN4's impact on telomere extension; (6) DNA damage response—evaluate using γH2AX foci formation and comet assays. These systems have demonstrated ZSCAN4's role in enhancing genome stability, extending telomeres, and improving karyotypes in stem cells .

How can researchers investigate ZKSCAN4 interactions with the glucocorticoid receptor?

To thoroughly investigate ZKSCAN4-glucocorticoid receptor interactions, employ this stepwise experimental framework: (1) Co-immunoprecipitation—precipitate endogenous ZKSCAN4 from appropriate cell lines (e.g., Hct116) and probe for glucocorticoid receptor co-precipitation; (2) Reciprocal IP—perform the reverse precipitation using anti-glucocorticoid receptor antibodies; (3) Domain mapping—generate truncated ZKSCAN4 mutants to identify interaction domains using GATEWAY cloning technology; (4) Fluorescent co-localization—utilize CFP-tagged ZKSCAN4 constructs to visualize nuclear co-localization with activated glucocorticoid receptor; (5) Functional reporter assays—assess effects on glucocorticoid receptor-driven reporter plasmids; (6) ChIP-seq overlap analysis—compare genome-wide binding sites of both proteins to identify regions of co-occupancy. This approach has successfully demonstrated that overexpressed ZKSCAN4 co-localizes with activated glucocorticoid receptor in granular nuclear structures and partially with chromatin regions characterized by histone H3 mono-methylated on lysine 4 (H3K4me1) .

What techniques can assess ZKSCAN4's role in specific chromatin contexts?

To characterize ZKSCAN4's function in chromatin contexts, implement these advanced methodological approaches: (1) ChIP-seq analysis—identify genome-wide binding sites, particularly at CA/TG microsatellite repeats forming Z-DNA structures; (2) Chromatin accessibility assays—employ ATAC-seq or DNase-seq to determine if ZKSCAN4 binding alters chromatin accessibility; (3) Histone modification mapping—use ChIP-seq for histone marks (particularly H3K4me1) to correlate ZKSCAN4 binding with specific chromatin states; (4) Chromosome conformation capture—apply Hi-C or related techniques to assess ZKSCAN4's impact on three-dimensional chromatin organization; (5) Z-DNA structure detection—implement Z-DNA-specific antibodies to correlate ZKSCAN4 binding with Z-DNA formation; (6) DNA damage assays—assess double-strand break formation at ZKSCAN4 binding sites. Research has shown that ZKSCAN4 binds to error-prone genomic regions and may enhance chromatin suppression at binding sites, suggesting a protective role against genome instability .

How should researchers address non-specific binding when using ZKSCAN4 antibodies?

To minimize non-specific binding with ZKSCAN4 antibodies, implement this systematic troubleshooting approach: (1) Antibody selection—prioritize affinity-purified antibodies demonstrated to detect endogenous ZKSCAN4 levels; (2) Blocking optimization—test alternative blocking agents (5% BSA, 2-5% normal serum matching secondary antibody species); (3) Antibody titration—perform dilution series to identify optimal concentration balancing specific signal and background; (4) Washing stringency—increase wash buffer salt concentration (150-500 mM NaCl) and detergent levels (0.1-0.3% Tween-20); (5) Validation controls—include ZKSCAN4 knockout/knockdown samples as negative controls; (6) Pre-adsorption—pre-incubate antibody with immunizing peptide to confirm specificity; (7) Secondary antibody optimization—test alternative secondary antibodies with minimal cross-reactivity. This approach has successfully addressed specificity concerns in experimental contexts involving ZKSCAN4 detection .

What methodological considerations are important when interpreting ChIP-seq data for ZKSCAN4?

When interpreting ZKSCAN4 ChIP-seq data, implement these critical analytical considerations: (1) Cell population heterogeneity—account for the low percentage of ZKSCAN4-positive cells (1-5% in mouse ES cells) by using enrichment strategies or induction methods (retinoic acid treatment or DUX4 overexpression); (2) Peak calling parameters—utilize MACS2 with q-value thresholds less than 0.2 and compare against appropriate controls; (3) Motif analysis interpretation—confirm enrichment of the TGCACAC binding motif using MEME-ChIP; (4) Genomic context evaluation—analyze peak distribution across genomic features (predominantly intergenic and intronic regions); (5) CA/TG microsatellite correlation—perform overlap analysis with RepeatMasker annotations; (6) Z-DNA structure potential—assess binding sites for susceptibility to form unstable left-handed duplexes; (7) Comparative analysis—normalize data appropriately when comparing between conditions (e.g., MAnorm for comparing ChIP peaks). These considerations align with published methodologies that successfully identified ZKSCAN4 binding sites in both mouse and human genomes .

How can researchers properly validate the specificity of ZKSCAN4 antibodies for their experiments?

To rigorously validate ZKSCAN4 antibody specificity, implement this comprehensive validation framework: (1) Western blot analysis—confirm single band of expected molecular weight in positive control samples (e.g., ZKSCAN4-overexpressing cells); (2) Knockout/knockdown controls—demonstrate signal reduction in CRISPR/Cas9 knockout or siRNA-treated samples; (3) Overexpression validation—show increased signal intensity proportional to overexpression levels; (4) Peptide competition—pre-incubate antibody with immunizing peptide to abolish specific signals; (5) Cross-reactivity assessment—test antibody against related ZKSCAN family members; (6) Multiple antibody concordance—compare staining patterns using different antibodies targeting distinct ZKSCAN4 epitopes; (7) Application-specific validation—perform additional controls tailored to specific applications (e.g., IgG controls for ChIP-seq). This approach aligns with validation strategies employed for the characterized ZKSCAN4 antibodies described in the literature .